StocksFundsScreenerSectorsWatchlists
SAGE

SAGE - Sage Therapeutics Inc Stock Price, Fair Value and News

18.75USD-0.29 (-1.52%)Delayed as of 28 Mar 2024, 01:05 pm ET

Market Summary

SAGE
USD18.75-0.29
Delayedas of 28 Mar 2024, 01:05 pm
-1.52%

SAGE Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

SAGE Stock Price

View Fullscreen

SAGE RSI Chart

SAGE Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-2.11

Price/Sales (Trailing)

13.3

Price/Free Cashflow

-2.11

SAGE Price/Sales (Trailing)

SAGE Profitability

Operating Margin

98.28%

Return on Equity

-67.73%

Return on Assets

-61.37%

Free Cashflow Yield

-47.28%

SAGE Fundamentals

SAGE Revenue

Revenue (TTM)

86.0M

Rev. Growth (Yr)

2.6K%

Rev. Growth (Qtr)

2.8K%

SAGE Earnings

Earnings (TTM)

-541.5M

Earnings Growth (Yr)

77.77%

Earnings Growth (Qtr)

83.78%

Breaking Down SAGE Revenue

52 Week Range

16.5259.99
(Low)(High)

Last 7 days

-3.8%

Last 30 days

-17.4%

Last 90 days

-12.0%

Trailing 12 Months

-49.5%

How does SAGE drawdown profile look like?

SAGE Financial Health

Current Ratio

10.51

SAGE Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

-9.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202308.6M9.8M86.0M
20226.3M6.2M6.5M7.7M
2021837.2M560.3M283.3M6.3M
20207.9M8.9M561.6M1.1B
2019062.5M34.7M6.9M
201800090.3M

Tracking the Latest Insider Buys and Sells of Sage Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 13, 2024
iguchi kimi
acquired
-
-
11,250
cfo & treasurer
Feb 13, 2024
cook anne marie
acquired
-
-
11,250
svp, gc & secretary
Feb 13, 2024
gault laura
acquired
-
-
11,250
chief medical officer
Feb 13, 2024
benecchi christopher
acquired
-
-
13,500
chief business officer
Jan 02, 2024
iguchi kimi
acquired
2,233
1.36
1,642
cfo & treasurer
Nov 28, 2023
iguchi kimi
sold (taxes)
-18,171
19.27
-943
cfo & treasurer
Nov 28, 2023
jonas jeffrey m
sold (taxes)
-75,827
19.27
-3,935
-
Nov 28, 2023
iguchi kimi
acquired
-
-
3,500
cfo & treasurer
Nov 28, 2023
cook anne marie
sold (taxes)
-22,623
19.27
-1,174
svp, gc & secretary
Nov 28, 2023
cook anne marie
acquired
-
-
4,000
svp, gc & secretary

1–10 of 50

Which funds bought or sold SAGE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-2.3
594
21,194
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
added
1,049
3,997,840
4,357,990
0.01%
Mar 11, 2024
VANGUARD GROUP INC
added
2.14
8,089,850
115,271,000
-%
Mar 05, 2024
Fisher Asset Management, LLC
added
8.08
1,135,660
9,359,810
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
204
14,208,000
20,651,800
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
26,463
569,466
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
23,000
456,000
-%
Feb 16, 2024
O'Dell Group, LLC
new
-
4,334
4,334
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
1,525,000
1,525,000
0.13%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-17.89
-1,622,000
10,362,000
-%

1–10 of 40

Are Funds Buying or Selling SAGE?

Are funds buying SAGE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SAGE
No. of Funds

Unveiling Sage Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
rtw investments, lp
8.7%
5,197,019
SC 13G
Feb 13, 2024
bb biotech ag
5.8%
3,505,000
SC 13G/A
Feb 13, 2024
vanguard group inc
8.86%
5,319,360
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
10.10%
6,061,996
SC 13G/A
Jan 26, 2024
blackrock inc.
7.8%
4,663,900
SC 13G/A
Jan 24, 2024
state street corp
6.53%
3,918,222
SC 13G
Jul 10, 2023
wellington management group llp
10.65%
6,363,630
SC 13G/A
Feb 17, 2023
bb biotech ag
5.2%
3,100,278
SC 13G
Feb 14, 2023
bb biotech ag
5.0%
2,950,278
SC 13G/A

Recent SEC filings of Sage Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
SC TO-I/A
SC TO-I/A
Mar 26, 2024
8-K
Current Report
Feb 21, 2024
SC TO-I/A
SC TO-I/A
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 14, 2024
10-K
Annual Report
Feb 14, 2024
8-K
Current Report

What is the Fair Value of SAGE?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Sage Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Sage Therapeutics Inc News

Latest updates
Defense World • 36 hours ago
MarketBeat • 26 Mar 2024 • 04:45 pm
Markets Insider • 26 Mar 2024 • 01:14 pm
Nasdaq • 20 Mar 2024 • 03:55 pm
Yahoo Finance • 15 Mar 2024 • 07:00 am
The Motley Fool • 4 months ago

Sage Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q42018Q32018Q2
Revenue2770.8%77,972,0002,716,0002,474,0002,864,5001,739,0001,501,0001,582,0001,642,0001,440,0001,643,0001,504,5001,366,0001,227,5001,089,0002,286,0001,960,0003,570,00025,177,50046,785,00068,392,50090,000,000
Cost Of Revenue-100.0%-905,000205,000143,000184,000200,000286,00087,000131,000148,000187,000136,000149,000110,000170,000-137,00044,000---
Operating Expenses-44.1%120,045,000214,565,000172,931,000156,767,000143,219,000129,908,000124,781,000127,129,000132,334,000109,664,00098,090,000135,211,000108,797,000140,056,000133,910,000176,598,000190,747,000177,330,000164,500,000128,745,000112,147,000
  S&GA Expenses-29.5%55,109,00078,142,00075,565,00067,329,00061,482,00052,411,00046,477,00051,599,00048,706,00043,346,00039,847,00053,498,50035,099,00038,224,00070,130,00085,129,00088,502,00088,227,00075,695,00053,693,00043,167,000
  R&D Expenses-36.9%64,329,500101,919,00097,161,00089,295,00081,553,00077,297,00078,018,00075,443,00083,497,00066,170,00058,056,00081,706,00074,078,00073,320,00063,610,00091,250,000102,108,00089,059,00088,805,00075,052,00068,980,000
EBITDA Margin-------74.06-73.13-71.93--0.540.54-1.21-76.26-26.97-16.38-6.44-5.02---
EBT Margin-------74.27-73.42-72.59--0.540.54-1.21-76.39-27.02-16.41-6.46-5.04---
Net Income83.8%-32,706,000-201,630,000-160,325,000-147,146,000-137,323,000-126,260,000-122,055,000-124,712,000-130,171,000-107,245,000-95,764,000974,895,000-105,735,000-136,347,000-126,740,000-168,653,000-179,958,000-168,221,000-158,388,000-122,918,000-16,978,000
Net Income Margin90.6%-6.29-66.98-76.97-69.31-78.95-81.62-76.77-72.592.27------------
Free Cashflow12.3%-119,407,000-136,194,000-131,630,000-127,214,000-119,229,000-106,561,000-107,969,000-97,501,000-68,826,000------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-7.1%8829501,0821,2211,3561,4861,6011,7061,8251,9272,0152,0812,1597398279451,0841,2041,3161,423953
  Current Assets-6.8%8699331,0641,2031,3371,4651,5791,6821,8011,9021,9892,0522,1226997858981,0351,1531,2641,372945
    Cash Equivalents-52.3%71.001491212071632002071792944225148991,661184258199127259166342191
  Net PPE-21.3%2.002.002.003.003.003.003.003.003.003.003.004.007.007.008.009.009.009.008.007.006.00
Liabilities-37.8%83.0013398.0088.0010410697.0087.0096.0092.0086.0077.0087.0081.0087.0096.0013912311310390.00
  Current Liabilities-37.8%83.0013397.0085.0099.0010089.0078.0085.0079.0072.0062.0067.0060.0064.0070.0011291.0079.0068.0086.00
Shareholder's Equity-2.1%8008179841,1331,2531,3801,5041,6191,7291,8361,9302,0032,0726587408499451,0811,2031,320863
  Retained Earnings-1.3%-2,569-2,536-2,335-2,175-2,028-1,900-1,700-1,617-1,495-1,400-1,240-1,100-1,037-2,000-1,900-1,770-1,643-1,500-1,294-1,126-963
  Additional Paid-In Capital0.4%3,3703,3583,3263,3143,2913,2763,2623,2483,2273,2073,1713,1373,1102,6692,6452,6212,5872,5552,4972,4471,827
Shares Outstanding0.1%60.0060.0060.0060.0060.0059.0059.0059.0059.0059.0058.0058.00---------
Float---2,471---1,686---2,934---2,121---9,274--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations12.0%-119,519-135,866-131,518-153,682-126,932-118,865-106,439-107,800-97,501-68,826-102,769-109,0861,010,971-91,016-118,984-136,691-116,726-128,702-133,344-149,934-101,778
  Share Based Compensation-54.9%12,94528,69111,69320,03815,24413,16914,63618,55320,64834,34227,66321,97620,74420,10824,03231,11030,67943,66934,76744,11631,640
Cashflow From Investing-73.8%42,061160,39245,593194,86789,777110,952134,262-9,558-30,261-24,983-288,388-658,81645,51913,513177,382206,270-17,916207,779-58,109-274,91038,418
Cashflow From Financing-109.5%-2622,7708472,67229.001,22913.001,799-1701,8166,0655,623419,6713,5453863,1602,16613,91915,343576,1961,628

SAGE Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Total revenue$ 86,455$ 7,686$ 6,308
Operating costs and expenses:   
Cost of revenues2,159813553
Research and development356,235326,163283,166
Selling, general and administrative274,524227,699183,498
Restructuring33,386  
Total operating costs and expenses666,304554,675467,217
Loss from operations(579,849)(546,989)(460,909)
Interest income, net38,74314,1902,883
Other income (expense), net(383)15134
Net loss$ (541,489)$ (532,784)$ (457,892)
Net loss per share - basic$ (9.05)$ (8.98)$ (7.8)
Net loss per share - diluted$ (9.05)$ (8.98)$ (7.8)
Weighted average number of common shares outstanding—basic59,836,44159,306,09458,670,230
Weighted average number of common shares outstanding—diluted59,836,44159,306,09458,670,230
Comprehensive loss:   
Net Income (Loss)$ (541,489)$ (532,784)$ (457,892)
Other comprehensive items:   
Unrealized gain (loss) on marketable securities9,392(7,546)(3,075)
Total comprehensive loss(532,097)(540,330)(460,967)
Product Revenue [Member]   
Total revenue10,454$ 7,686$ 6,308
License And Milestone Revenue - Related Party [Member]   
Total revenue75,000  
Collaboration Revenue - Related Party [Member]   
Total revenue824  
Other Collaboration Revenue [Member]   
Total revenue$ 177  

SAGE Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 70,992$ 162,700
Marketable securities682,1921,109,794
Prepaid expenses and other current assets31,82550,826
Collaboration receivable - related party$ 83,009$ 13,660
Accounts Receivable, after Allowance for Credit Loss, Current, Related Party, Type [Extensible Enumeration]Related Party [Member]Related Party [Member]
Restricted cash$ 1,332$ 0
Total current assets869,3501,336,980
Property and equipment, net1,9212,898
Restricted cash01,269
Right-of-use operating asset4,45810,532
Other long-term assets6,5484,770
Total assets882,2771,356,449
Current liabilities:  
Accounts payable10,31818,950
Accrued expenses67,26472,666
Operating lease liability, current portion5,1657,643
Total current liabilities82,74799,259
Operating lease liability, net of current portion04,491
Other liabilities0100
Total liabilities82,747103,850
Commitments and contingencies (Note 5)
Stockholders’ equity:  
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at December 31, 2023 and December 31, 2022; no shares issued or outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value per share; 120,000,000 shares authorized at December 31, 2023 and December 31, 2022; 60,046,676 and 59,512,158 shares issued at December 31, 2023 and December 31, 2022; 60,043,643 and 59,509,125 shares outstanding at December 31, 2023 and December 31, 202266
Treasury stock, at cost, 3,033 shares at December 31, 2023 and December 31, 2022(400)(400)
Additional paid-in capital3,370,3973,291,369
Accumulated deficit(2,569,659)(2,028,170)
Accumulated other comprehensive loss(814)(10,206)
Total stockholders’ equity799,5301,252,599
Total liabilities and stockholders’ equity$ 882,277$ 1,356,449
SAGE
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.sagerx.com
 EMPLOYEES689

Sage Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Sage Therapeutics Inc? What does SAGE stand for in stocks?

SAGE is the stock ticker symbol of Sage Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sage Therapeutics Inc (SAGE)?

As of Wed Mar 27 2024, market cap of Sage Therapeutics Inc is 1.14 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SAGE stock?

You can check SAGE's fair value in chart for subscribers.

What is the fair value of SAGE stock?

You can check SAGE's fair value in chart for subscribers. The fair value of Sage Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sage Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SAGE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sage Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SAGE is over valued or under valued. Whether Sage Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sage Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SAGE.

What is Sage Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, SAGE's PE ratio (Price to Earnings) is -2.11 and Price to Sales (PS) ratio is 13.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SAGE PE ratio will change depending on the future growth rate expectations of investors.